{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T23:31:43Z","timestamp":1769729503418,"version":"3.49.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2016,11,25]],"date-time":"2016-11-25T00:00:00Z","timestamp":1480032000000},"content-version":"vor","delay-in-days":177,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Department of Radiology and Radiation Oncology, Graduate School of Medicine and Dental Sciences, Niigata University"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We investigated the outcomes of treatment for patients with localized prostate cancer (PCa) treated with 3D conformal radiation therapy (3D-CRT) followed by two-fraction high-dose-rate brachytherapy within a single day (2-fr.-HDR-BT\/day) at a single institution. A total of 156 consecutive Asian males (median age, 67 years) were enrolled. To compare our findings with those of other studies, we analyzed our results using the D'Amico classification, assigning the patients to low- ( n = 5; 3.2%), intermediate- ( n = 36; 23.1%) and high-risk ( n = 115; 73.7%) groups (Stage T3 PCa patients were classified as high-risk). One patient in the D'Amico low-risk group (20%), 13 intermediate-risk patients (36.1%) and 99 high-risk patients (86.1%) underwent androgen deprivation therapy. We administered a prescription dose of 39 Gy in 13 fractions of 3D-CRT combined with 18 Gy of HDR-BT in two 9-Gy fractions delivered within a single day. We did not distinguish between risk groups in determining the prescription dose. The median follow-up period was 38 months. Of the 156 patients, one died from primary disease and five died from other diseases. The 3-year overall survival (OS) rates were 100%, 100% and 93.7%, and the 3-year \u2018biochemical no evidence of disease (bNED)\u2019 rates were 100%, 100% and 96.9% for the D'Amico low-, intermediate- and high-risk groups, respectively. No patient developed \u2265 Grade 3 early toxicity. The Grade 3 late genitourinary toxicity rate was 2.6%, and no \u2265 Grade 3 late gastrointestinal toxicity occurred. The efficacy and safety of this study were satisfactory, and longer-term follow-up is necessary.<\/jats:p>","DOI":"10.1093\/jrr\/rrw003","type":"journal-article","created":{"date-parts":[[2016,3,17]],"date-time":"2016-03-17T00:58:39Z","timestamp":1458176319000},"page":"280-287","source":"Crossref","is-referenced-by-count":9,"title":["Two-fraction high-dose-rate brachytherapy within a single day combined with external beam radiotherapy for prostate cancer: single institution experience and outcomes"],"prefix":"10.1093","volume":"57","author":[{"given":"Junyang","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoki","family":"Kaidu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuta","family":"Sasamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumio","family":"Ayukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuko","family":"Yamana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiraku","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gen","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuya","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eisuke","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kasahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiko","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidefumi","family":"Aoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2016,6,21]]},"reference":[{"key":"2020010903184352400_RRW003C1","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.brachy.2011.09.008","article-title":"American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy","volume":"11","author":"Yamada","year":"2012","journal-title":"Brachytherapy"},{"key":"2020010903184352400_RRW003C2","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.radonc.2013.05.002","article-title":"GEC\/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update","volume":"107","author":"Hoskin","year":"2013","journal-title":"Radiother Oncol"},{"key":"2020010903184352400_RRW003C3","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.ijrobp.2003.08.003","article-title":"Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer","volume":"58","author":"Galalae","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020010903184352400_RRW003C4","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.ijrobp.2010.08.046","article-title":"American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of high-dose-rate brachytherapy","volume":"79","author":"Erickson","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020010903184352400_RRW003C5","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.radonc.2004.10.014","article-title":"Long-term outcome of high dose rate brachytherapy in radiotherapy of localised prostate cancer","volume":"74","author":"Astrom","year":"2005","journal-title":"Radiother Oncol"},{"key":"2020010903184352400_RRW003C6","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ijrobp.2009.10.035","article-title":"Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy","volume":"79","author":"Martinez","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020010903184352400_RRW003C7","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1120\/jacmp.v11i4.3193","article-title":"Impact of multileaf collimator width on intraprostatic dose painting plans for dominant intraprostatic lesion of prostate cancer","volume":"11","author":"Abe","year":"2010","journal-title":"J Appl Clin Med Phys"},{"key":"2020010903184352400_RRW003C8","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0167-8140(97)00122-9","article-title":"Irradiation of localized prostatic carcinoma with a combination of high dose rate iridium-192 brachytherapy and external beam radiotherapy with three target definitions and dose levels inside the prostate gland","volume":"44","author":"Borghede","year":"1997","journal-title":"Radiother Oncol"},{"key":"2020010903184352400_RRW003C9","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.ijrobp.2004.08.014","article-title":"High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results","volume":"61","author":"Demanes","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020010903184352400_RRW003C10","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1016\/j.ijrobp.2011.08.002","article-title":"External-beam radiation therapy and high-dose rate brachytherapy combined with long-term androgen deprivation therapy in high and very high prostate cancer: preliminary data on clinical outcome","volume":"82","author":"Martinez-Monge","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020010903184352400_RRW003C11","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1097\/01.ju.0000158155.33890.e7","article-title":"The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy","volume":"173","author":"Cooperberg","year":"2005","journal-title":"J Urol"},{"key":"2020010903184352400_RRW003C12","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D'Amico","year":"1998","journal-title":"JAMA"},{"key":"2020010903184352400_RRW003C13","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.acuro.2014.03.003","article-title":"Optimizing D'Amico risk groups in radical prostatectomy through the addition of magnetic resonance imaging data","volume":"38","author":"Algarra","year":"2014","journal-title":"Actas Urol Esp"},{"key":"2020010903184352400_RRW003C14","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ijrobp.2010.01.016","article-title":"Dosimetric impact of interfraction catheter movement in high-dose rate prostate brachytherapy","volume":"80","author":"Foster","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020010903184352400_RRW003C15","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG\u2013ASTRO Phoenix Consensus","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020010903184352400_RRW003C16","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"2020010903184352400_RRW003C17","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1200\/JCO.2000.18.15.2869","article-title":"Matched-pair analysis of conformal high-dose-rate brachytherapy boost versus external-beam radiation therapy alone for locally advanced prostate cancer","volume":"18","author":"Kestin","year":"2000","journal-title":"J Clin Oncol"},{"key":"2020010903184352400_RRW003C18","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ijrobp.2012.07.006","article-title":"Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs external beam radiation therapy alone for prostate cancer","volume":"85","author":"Khor","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020010903184352400_RRW003C19","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.radonc.2012.01.007","article-title":"Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer","volume":"103","author":"Hoskin","year":"2012","journal-title":"Radiother Oncol"},{"key":"2020010903184352400_RRW003C20","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ijrobp.2010.09.021","article-title":"High-dose-rate brachytherapy boost for prostate cancer: comparison of two different fractionation schemes","volume":"82","author":"Kaprealian","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020010903184352400_RRW003C21","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1093\/jrr\/rrt027","article-title":"The emerging role of high-dose-rate (HDR) brachytherapy as monotherapy for prostate cancer","volume":"54","author":"Yoshioka","year":"2013","journal-title":"J Radiat Res"},{"key":"2020010903184352400_RRW003C22","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.juro.2011.09.050","article-title":"High dose brachytherapy as monotherapy for intermediate risk prostate cancer","volume":"187","author":"Rogers","year":"2012","journal-title":"J Urol"},{"key":"2020010903184352400_RRW003C23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2015.05.044","article-title":"(3 June 2015) High-dose-rate brachytherapy as monotherapy for intermediate- and high-risk prostate cancer: clinical results for a median 8-year follow-up","author":"Yoshioka","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020010903184352400_RRW003C24","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.brachy.2015.01.004","article-title":"High-dose-rate brachytherapy as a monotherapy for prostate cancer\u2014single-institution results of the extreme fractionation regimen","volume":"14","author":"Kukielka","year":"2015","journal-title":"Brachytherapy"},{"key":"2020010903184352400_RRW003C25","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/jrr\/rrt134","article-title":"Analysis of prognostic factors in localized high-risk prostate cancer patients treated with HDR brachytherapy, hypofractionated 3D-CRT and neoadjuvant\/adjuvant androgen deprivation therapy (trimodality therapy)","volume":"55","author":"Aoki","year":"2014","journal-title":"J Radiat Res"},{"key":"2020010903184352400_RRW003C26","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1093\/jrr\/rrt128","article-title":"High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term hormonal therapy for high-risk and very high-risk prostate cancer: outcomes after 5-year follow-up","volume":"55","author":"Ishiyama","year":"2014","journal-title":"J Radiat Res"},{"key":"2020010903184352400_RRW003C27","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.juro.2013.02.012","article-title":"Outcome and toxicity for patients treated with intensity modulated radiation therapy for localized prostate cancer","volume":"190","author":"Vora","year":"2013","journal-title":"J Urol"},{"key":"2020010903184352400_RRW003C28","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.ijrobp.2012.05.023","article-title":"Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer","volume":"85","author":"Spratt","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020010903184352400_RRW003C29","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/cam4.261","article-title":"Late toxicity and quality of life after definitive treatment of prostate cancer: redefining optimal rectal sparing constraints for intensity-modulated radiation therapy","volume":"3","author":"Chennupati","year":"2014","journal-title":"Cancer Med"},{"key":"2020010903184352400_RRW003C30","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.radonc.2014.04.005","article-title":"Integrated models for the prediction of late genitourinary complaints after high-dose intensity modulated radiotherapy for prostate cancer: making informed decisions","volume":"112","author":"De Langhe","year":"2014","journal-title":"Radiother Oncol"},{"key":"2020010903184352400_RRW003C31","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ijrobp.2008.11.006","article-title":"Genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external beam radiotherapy for localized prostate cancer: an analysis to determine the correlation between dose\u2013volume histogram parameters in HDR brachytherapy and severity of toxicity","volume":"75","author":"Ishiyama","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020010903184352400_RRW003C32","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.brachy.2014.03.002","article-title":"High-dose-rate brachytherapy as monotherapy for prostate cancer","volume":"13","author":"Demanes","year":"2014","journal-title":"Brachytherapy"}],"container-title":["Journal of Radiation Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jrr\/article-pdf\/57\/3\/280\/31614784\/rrw003.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jrr\/article-pdf\/57\/3\/280\/31614784\/rrw003.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T08:27:49Z","timestamp":1578558469000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jrr\/article\/57\/3\/280\/2580386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,1]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,6,21]]},"published-print":{"date-parts":[[2016,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jrr\/rrw003","relation":{},"ISSN":["0449-3060","1349-9157"],"issn-type":[{"value":"0449-3060","type":"print"},{"value":"1349-9157","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,6]]},"published":{"date-parts":[[2016,6,1]]}}}